**Core Concept**
Sulphonyl ureas are a class of oral hypoglycemic agents used to manage type 2 diabetes mellitus. They work by inhibiting the enzyme ATP-sensitive potassium channels in the pancreatic beta cells, leading to increased insulin release. This class of drugs is often used in combination with other antidiabetic agents.

**Why the Correct Answer is Right**
The sulphonyl urea compounds work by binding to the sulphonyl urea receptor (SUR1) on the beta cells of the pancreas. This binding causes a conformational change in the ATP-sensitive potassium channels, which leads to the closure of these channels and an increase in intracellular ATP. The increase in ATP then activates the protein kinase A (PKA) pathway, leading to the exocytosis of insulin-containing granules and an increase in insulin release. This mechanism is specific to sulphonyl urea compounds and is not seen with other classes of antidiabetic agents.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it does not specify a sulphonyl urea compound. Without the correct name, it is impossible to determine whether this option is a sulphonyl urea compound or not.
**Option B:** This option is incorrect because it may be a sulphonyl urea compound, but without the name, it is impossible to verify its classification.
**Option C:** This option is incorrect because it is a sulphonyl urea compound, not an exception to the class.

**Clinical Pearl / High-Yield Fact**
It is essential to remember that sulphonyl urea compounds are contraindicated in patients with a history of hypoglycemia, heart failure, and chronic liver disease. Additionally, sulphonyl urea compounds can cause hypoglycemia when used in combination with other antidiabetic agents such as insulin and metformin.

**Correct Answer:** D.